Thank you very much.
I want to follow up with...I think it's Ms. Lamarre, your presentation. You made three recommendations, or you've captured three recommendations—a monitoring unit, a legislative framework, and a list of essential drugs—and you've referenced the United States and France in your remarks.
I'm wondering if you are aware of other best practices in other countries that you'd be willing to share with us that support your recommendations or would add to them.